Invesco Mutual Fund Opens Pharma And Healthcare Fund NFO Until September 1

Invesco Mutual Fund has launched the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme focused on pharmaceutical, healthcare and allied sectors. The New Fund Offer (NFO) opened for subscription on August 18, 2026, and will close on September 1, 2026.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

The scheme will invest across different parts of the healthcare value chain, including pharmaceutical companies, hospitals, diagnostic businesses, contract development and manufacturing organisations (CDMOs), contract research organisations (CROs), medical device makers and healthcare service providers. It will also have exposure to insurance and other related healthcare segments.

Fund To Focus On India’s Expanding Healthcare Ecosystem

According to Invesco Mutual Fund, the scheme has been introduced to participate in the changes taking place across India’s healthcare industry. The fund house has pointed to factors such as favourable demographics, wider access to healthcare, increasing insurance coverage and India’s established position in global pharmaceutical manufacturing.

The investment universe will not be limited to traditional pharmaceutical companies. The fund can also invest in hospitals, diagnostics, CDMOs, CROs, medical devices and other emerging areas within healthcare and life sciences.

The AMC said India’s scale, skilled workforce, manufacturing capabilities and expanding innovation base have strengthened its position in the global healthcare ecosystem. Rising healthcare spending, an ageing population and the growing incidence of lifestyle-related diseases are among the factors highlighted by the fund house.

Aditya Khemani To Manage The Scheme

Aditya Khemani, Head of Equity and Fund Manager at Invesco Mutual Fund, will manage the new scheme. The fund will use the BSE Healthcare TRI as its benchmark.

Khemani said India’s healthcare industry is going through structural changes, with higher healthcare consumption supported by demographic trends and improving affordability. He added that the country is also strengthening its role in pharmaceutical and healthcare innovation globally.

The fund manager said the scheme will look at opportunities across domestic pharmaceuticals, hospitals, diagnostics, CDMOs and newer healthcare businesses. The investment approach will focus on businesses with sustainable competitive advantages and growth visibility across the healthcare ecosystem.

NFO Covers Multiple Healthcare Segments

The fund’s proposed portfolio gives it the flexibility to invest across established and emerging healthcare businesses rather than concentrating solely on pharmaceutical companies. This includes companies involved in healthcare delivery, research, manufacturing, diagnostics, medical technology and insurance.

The AMC has also highlighted growing health insurance penetration and healthcare infrastructure development as factors shaping the sector. Global outsourcing trends are another area identified by the fund house as relevant to Indian healthcare and life sciences companies.

The Invesco India Pharma and Healthcare Fund NFO will remain open until September 1, giving investors a defined subscription window before the scheme moves beyond its initial offer period. The fund will subsequently operate as an open-ended equity scheme with its investment mandate centred on pharma, healthcare and allied businesses.